<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1011">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093714</url>
  </required_header>
  <id_info>
    <org_study_id>FDL169-2015-04</org_study_id>
    <nct_id>NCT03093714</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flatley Discovery Lab LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flatley Discovery Lab LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, placebo-controlled, dose-escalation study. Enrollment is
      planned to occur at approximately 14 global sites. Approximately 24 subjects with CF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, randomized double-blind, placebo-controlled dose-escalation and
      parallel-arm, dose-ranging study. Enrollment is planned to occur at approximately 14 global
      sites. Approximately 24 subjects with CF who are homozygous for the F508del-CFTR mutation
      will be enrolled in two cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Investigator</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>28 days</time_frame>
    <description>Safety and tolerability of FDL169 as determined by the incidence of adverse events (AEs) and serious adverse events (SAEs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, Cmax</measure>
    <time_frame>28 days</time_frame>
    <description>The pharmacokinetic parameters of FDL169: maximal plasma concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, Tmax</measure>
    <time_frame>28 days</time_frame>
    <description>The pharmacokinetic parameters of FDL169: maximal concentration (Tmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, AUC</measure>
    <time_frame>28 days</time_frame>
    <description>The pharmacokinetic parameters of FDL169: area under the plasma concentration curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, CL/F</measure>
    <time_frame>28 days</time_frame>
    <description>The pharmacokinetic parameters of FDL169: clearance (CL/F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters, V/F</measure>
    <time_frame>28 days</time_frame>
    <description>The pharmacokinetic parameters of FDL169: apparent volume of distribution (V/F).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>FDL 169 test formulation (Dose Level 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose (Dose Level 1) FDL 169 test formulation administered as repeat doses in CF subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDL 169 test formulation (Dose Level 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose (Dose Level 2) FDL 169 test formulation administered as repeat doses in CF subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FDL 169 test formulation ( Dose Level 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple dose (Dose Level 3) FDL 169 test formulation administered as repeat doses in CF subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple dose placebo as repeat doses in CF subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FDL169</intervention_name>
    <description>CFTR corrector</description>
    <arm_group_label>FDL 169 test formulation (Dose Level 1)</arm_group_label>
    <arm_group_label>FDL 169 test formulation (Dose Level 2)</arm_group_label>
    <arm_group_label>FDL 169 test formulation ( Dose Level 3)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for FDL169</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with a confirmed diagnosis of CF defined as a sweat chloride
             value ≥60 mmol/L by quantitative pilocarpine iontophoresis or two CF-causing
             mutations,documented in the subject's medical record or confirmed at screening.

          -  Age 18 and above on the date of informed consent.

          -  Weight ≥40 kg.

          -  Homozygous for the F508del-CFTR mutation. Genotyping to be confirmed at screening.

          -  Ability to perform a valid, reproducible spirometry test with demonstration of a
             forced expiratory volume in 1 sec (FEV1) &gt;40% of predicted normal for age, sex and
             height.

          -  Screening laboratory tests with no clinically significant abnormalities that would
             interfere with the study assessments (as judged by the Investigator).

          -  Subjects who are sexually active must agree to follow the study's contraception
             requirements.

        Exclusion Criteria:

          -  An acute upper or lower respiratory tract infection, pulmonary exacerbation, or
             changes in therapy for pulmonary disease within 4 weeks prior to Day 1.

          -  Major complications of lung disease (including massive hemoptysis, pneumothorax, or
             pleural effusion) within 8 weeks prior to screening.

          -  Impaired renal function or known portal hypertension.

          -  History of prolonged QT and/or QTcF (Fridericia's correction) interval (&gt;450 msec) or
             QTcF &gt;450 msec at Screening.

          -  History of solid organ or hematological transplantation.

          -  History of alcohol abuse or drug addiction (including cannabis, cocaine and opiates)
             during the past year, (as judged by the Investigator).

          -  Use of ivacaftor or lumacaftor, within 4 weeks of Day 1

          -  Any change (initiation, change in type of drug, dose modification, schedule
             modification, interruption, discontinuation, or re-initiation) in a chronic
             treatment/prophylaxis regimen for CF or for CF-related conditions within 4 weeks
             prior to Day 1.

          -  Ongoing immunosuppressive therapy (including systemic corticosteroids).

          -  Hemoglobin &lt;10 g/dL.

          -  Abnormal liver function, at screening.

          -  Abnormal renal function at screening.

          -  Ongoing participation in another clinical study or prior participation without
             appropriate washout (minimum of 10 half- lives or 30 days, whichever is longer) prior
             to Screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudia Ordonez, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flatley Discovery Lab</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jingwen Chai</last_name>
    <phone>617-904-3705</phone>
    <email>jingwen.chai@flatleydiscoverylab.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Timothy O'Toole, MS</last_name>
    <phone>617-904-3708</phone>
    <email>timothyotoole@flatleydiscoverylab.com</email>
  </overall_contact_backup>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>March 16, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cystic Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
